Overview

Acitretin Plasma Levels Under Hemodialysis

Status:
Withdrawn

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Phase:

Phase 4

Details

Lead Sponsor:

Günther Hofbauer

Collaborator:

University of Zurich

Treatments:

Acitretin